FDA Grants Accelerated Approval for Regeneron's Landmark Hearing Loss Gene Therapy

Key Facts

Regeneron Pharmaceuticals has achieved a significant milestone as the FDA granted accelerated approval for Otarmeni, the first gene therapy designed to restore neurosensory function in patients with severe hearing loss. The approval follows successful results from the Phase I/II CHORD trial, which demonstrated hearing restoration in patients with specific OTOF gene variants. Parallel to this, Intellia Therapeutics reported positive Phase III data for its hereditary angioedema treatment, signaling plans for a rolling BLA submission. These dual breakthroughs highlight a period of intense innovation and clinical de-risking within the biotechnology sector. Investors are closely monitoring the commercial rollout of these therapies and their potential impact on long-term revenue streams. This development marks a strategic expansion for Regeneron into the high-growth gene therapy market.